DealPulse Signal Wk 31: One Buyer Paid Everything, Another Paid a Fifth
Two immunology deals, five days apart. argenx paid 100% on signing for Phase 1b. J&J paid 22% for preclinical. Both are correctly priced.
The Beats
Analysis
The Briefs
Congress Exempted the Medically Frail. The Coding System Cannot Find Them.
An FDA Panel Voted 9-3 Against Capricor on Cardiomyopathy and Never Voted on the Endpoint That Passed
Revtorpyk Got Its NCCN Category 1 Listing Two Months Before Celcuity Can Sell a Single Vial
NICE Backed Aficamten the Same Day the MHRA Authorised It, at a Price It Will Not Disclose
J&J Paid $785 Million for a Look at Something That Has Never Been in a Human
